Oncology Institute (TOIIW) Cash & Equivalents (2019 - 2026)

Oncology Institute has reported Cash & Equivalents for 8 years, with the latest figure at $30.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 23.8% year-over-year to $30.3 million; the trailing twelve-month figure through Mar 2026 stood at $30.3 million (down 23.8% YoY), and the FY2025 full-year result was $33.6 million, down 32.42% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $30.3 million, down from $33.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $95.5 million in Q1 2022, with the low at $14.0 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $39.5 million across 5 years, with a median of $33.6 million in 2025.
• The largest YoY upside for Cash & Equivalents was 432.65% in 2022 against a maximum downside of 87.84% in 2022.
• Oncology Institute's Cash & Equivalents stood at $14.0 million in 2022, then surged by 139.03% to $33.5 million in 2023, then jumped by 48.32% to $49.7 million in 2024, then slumped by 32.42% to $33.6 million in 2025, then dropped by 9.79% to $30.3 million in 2026.
• The last three Cash & Equivalents figures came in at $30.3 million (Q1 2026), $33.6 million (Q4 2025), and $27.7 million (Q3 2025), per Business Quant data.